Hostname: page-component-7b9c58cd5d-hpxsc Total loading time: 0 Render date: 2025-03-15T14:52:40.365Z Has data issue: false hasContentIssue false

Effects of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance

Published online by Cambridge University Press:  27 July 2020

Hatice Güneş*
Affiliation:
Department of Pediatrics, Sutcu Imam University, Kahramanmaras, Turkey
Hakan Güneş
Affiliation:
Department of Cardiology, Sutcu Imam University, Kahramanmaras, Turkey
Şebnem Özmen
Affiliation:
Department of Pediatrics, Sutcu Imam University, Kahramanmaras, Turkey
Enes Çelik
Affiliation:
Department of Cardiology, Sutcu Imam University, Kahramanmaras, Turkey
Fatih Temiz
Affiliation:
Department of Pediatric Endocrinology and Metabolism, Sutcu Imam University, Kahramanmaras, Turkey
*
Author for correspondence: Assistant Prof., Hatice Güneş, MD, Department of Pediatrics, Kahramanmaras Sutcu Imam, University School of Medicine, Kahramanmaras, Turkey. Tel: +90 344 3003785; Fax: +90 344 300 3409. E-mail: drhaticegunes82@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Obesity is usually related to insulin resistance and glucose metabolism disorders. The relationship between insulin resistance and epicardial adipose tissue and atrial electromechanical delay has been described in previous studies.

Aim:

This study aims to demonstrate the effects of metformin on epicardial adipose tissue and electromechanical delay in patients using metformin for insulin resistance.

Materials and methods:

A total of 30 patients using metformin for insulin resistance were included in the study. Pre-treatment and post-treatment epicardial adipose tissue and electromechanical delay were evaluated.

Results:

There was a statistically significant decrease in epicardial adipose tissue thickness after 3 months of metformin therapy (6.4 ± 2.1 versus 4.7 ± 2.0; p = 0.008). Furthermore, the inter-atrial and intra-atrial electromechanical delay also significantly decreased after 3 months of metformin monotherapy (23.6 ± 8.2 versus 18.1 ± 5.8; p < 0.001, 9.1 ± 2.9 versus 6.3 ± 3.6; p = 0.003, respectively).

Conclusion:

In this study, we show that metformin monotherapy significantly decreases epicardial adipose tissue thickness and electromechanical delay in obese children.

Type
Original Article
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Obesity is an important health issue worldwide due to its increasing prevalence as well as its occurrence at an early age.1Reference de Onis, Blössner and Borghi3 Obesity is usually related to insulin resistance and glucose metabolism disorders. Adipose tissue deposited in subcutaneous and visceral tissues plays an important role in the development of insulin resistance due to its secretion of active proteins.Reference Iacobellis and Leonetti4 The first step of treatment in obese children with insulin resistance is planning the diet, changing lifestyle and increasing physical activity.Reference Tagi, Giannini and Chiarelli5 Pharmacological treatment is given to cases when primary prevention methods are insufficient.Reference Akhlaghi, Matson, Mohammadpour, Kelly and Karimani6,Reference Chao, Wadden, Berkowitz, Chao and Wadden7 It has been demonstrated in randomised clinical studies that metformin which is a biguanide derivative reduces insulin resistance in adults by decreasing fasting glucose level and insulin concentrations. Obesity at an early age is closely related to ischemic heart disease as well as it is also closely related to non-ischemic heart diseases such as arrhythmia (especially increases the risk of atrial fibrillation).Reference Khokhar, Umpaichitra, Chin and Perez-Colon8Reference El-Assaad, Al-Kindi, Saarel and Aziz11 It has been known that electromechanical delay predicts atrial fibrillation and it has been demonstrated that obese children have electromechanical delay.Reference Temiz, Güneş and Güneş12 However, the effects of metformin on electromechanical delay in obese children with insulin resistance have not been known.

Epicardial adipose tissue correlates with visceral adipose tissue and causes a local inflammatory response and increased insulin resistance with similar pathophysiology which ultimately results in cardiovascular risk increase.Reference Ziyrek, Kahraman, Ozdemir and Dogan13 Although findings are indicating a decreasing effect of metformin on epicardial adipose tissue in adults, there has been no information related to this issue in the paediatric population.

The study aimed to evaluate the effects of metformin on electromechanical delay and epicardial adipose tissue of children using metformin for insulin resistance.

Materials and methods

Study population

In this prospective observational study, a total of 87 patients aged between 8 and 18 years who had been followed in Kahramanmaraş Sütçü İmam University Pediatric Endocrinology and Metabolism Outpatient Clinic between August 2018 and March 2020 was screened. Among these patients, 35 patients who could not lose weight despite diet and exercise and received metformin for insulin resistance were analysed. Five patients who did not have echocardiographic epicardial adipose tissue measurement and electromechanical delay measurement before treatment were excluded from the study. Thirty patients whose clinical features were recorded with echocardiographic and laboratory values were included in the study. Metformin was started to patients for insulin resistance with an appropriate dose to their height/weight. Clinical, echocardiographic and laboratory findings of patients were evaluated after 3 months of metformin treatment. Anthropometric measurements such as weight and height were performed by endocrinology outpatient clinic nurse while patients were wearing only underwear. Body mass index was calculated as a person’s weight in kilograms divided by the square of height in metres. Homeostatic Model Assessment for Insulin Resistance value was calculated with the formula of Fasting Glucose (mg/dl) × Fasting Insulin (uIU/ml)/405.Reference van der Aa, Fazeli Farsani, Kromwijk, de Boer, Knibbe and van der Vorst14,Reference Shashaj, Luciano and Contoli15

Pre-treatment and post-treatment echocardiographic evaluations of all patients were performed by the same cardiology specialist. Epicardial adipose tissue was evaluated with standard echocardiographic evaluation, whereas atrial electromechanical delay was evaluated with tissue Doppler. The same cardiologist evaluated pre-discharge trans-thoracic echocardiography results of 20 randomly selected patients to assess the reproducibility of epicardial adipose tissue thickness and tissue Doppler parameters for the atrial electromechanical delay. Using the Bland–Altman method, the mean difference in terms of intra-observation was 3.8% (0.23 ± 0.54%), indicating good reproducibility.

The effects of metformin on all parameters were evaluated after recording demographics and laboratory values.

Echocardiography

Echocardiographic assessment and measurement of epicardial adipose tissue were done by identifying the echo-free space between the outer lining of the myocardium and the visceral layer of the pericardium. Its measurement was made perpendicularly to the free wall of the right ventricle in the parasternal long-axis window. The level of the measurement was at mid ventricle and the timing was set to end-diastole, with an average of three cardiac cycles being taken. Aortic annulus was accepted as the anatomic landmark to align the ultrasound beam perpendicular to the right ventricular free wall.Reference Iacobellis, Lonn and Lamy16

Tissue Doppler echocardiography

The pulsed Doppler sample volume was placed at the level of the left ventricle (lateral mitral annulus, septal mitral annulus) and right ventricle (tricuspid annulus) from an apical four-chamber view. The time interval from the onset of the P-wave on surface ECG to the beginning of the late diastolic wave (Am), which is called PA, was gained from the lateral mitral annulus (PA lateral), the septal mitral annulus (PA septal) and RV tricuspid annulus (PA tricuspid). The difference between PA septum and PA tricuspid (PA septum − PA tricuspid) was identified as an intra-atrial electromechanical delay, while the difference between PA lateral and PA tricuspid (PA lateral − PA tricuspid) was identified as an inter-atrial electromechanical delay.Reference Gunes, Sokmen and Kaya17

Statistical analysis

All statistical analyses were performed using SPSS version 14 (SPSS Inc., Chicago, Illinois, United States of America) software package. Statistical significance was set to a two-sided p-value < 0.05. Data were expressed as mean ± standard deviation for continuous variables and as counts and percentages for categorical variables. The normality assumption of the data was determined using the Kolmogorov–Smirnov test. The Student’s t-test was used to compare continuous variables, while the chi-square and Fisher’s exact tests were used to compare categorical variables. Correlations of continuous variables were assessed using Pearson correlation analysis.

Results

The mean age of included 30 patients was 14.3 ± 2.1. Seventeen (57%) patients were female, and 13 (43%) were male. Serum insulin levels significantly decreased after 3 months of metformin monotherapy (21.4 ± 7.5 mIU/L versus 12.5 ± 6.1; p < 0.001). There was no significant decrease between pre-treatment and post-treatment serum glucose levels (89 ± 7.7mg/dl versus 87.2 ± 5.7; p = 0.257). However, there was a significant decrease in Homeostatic Model Assessment for Insulin Resistance value after 3 months of metformin treatment (4.7 ± 1.6 versus 2.7 ± 1.4; p < 0.001). Similarly, weight and body mass index significantly decreased after 3 months of metformin monotherapy (91.8 ± 17.2 kg versus 85.4 ± 13.4; p < 0.001 and 34.0 ± 7.6 versus 31.8 ± 7.3; p < 0.001, respectively) (Table 1).

Table 1. Baseline characteristics of study patients

BMI = body mass index, HOMA-IR = Homeostatic Model Assessment for Insulin Resistance.

Data are presented as mean ± standard deviation, and p < 0.05 was considered statistically significant.

Epicardial adipose tissue thickness significantly decreased after 3 months of metformin monotherapy (6.4 ± 2.1 mm versus 4.7 ± 2.0; p = 0.008) (Fig 1, Table 2). Furthermore, inter-atrial electromechanical delay and intra-atrial electromechanical delay also significantly decreased after 3 months of metformin monotherapy (23.6 ± 8.2 ms versus 18.1 ± 5.8; p < 0,001 and 9.1 ± 2.9 ms versus 6.3 ± 3.6; p = 0.003, respectively) (Table 2).

Figure 1. The comparison of epicardial adipose tissue thickness (EAT) values before and after metformin therapy

Table 2. Comparison of the atrial electromechanical coupling parameters measured by tissue Doppler imaging

PA = time interval from the onset of P-wave on surface ECG to the beginning of Am wave interval with tissue Doppler echocardiography; EMD = electromechanical delay; EAT = epicardial adipose tissue.

Data are presented as mean ± standard deviation, and p < 0.05 was considered statistically significant.

Discussion

This study is the first study demonstrating the effect of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children. In our study, it was observed that epicardial adipose tissue, inter-atrial and intra-atrial conduction significantly decreased in obese children using metformin.

Epicardial adipose tissue is the visceral adipose deposit causing local inflammation with pathophysiologic features of other visceral adipose tissue.Reference Gastaldelli and Basta18Reference Marchington, Mattacks and Pond21 It has been shown that adipose distribution in the abdominal region is correlated with epicardial adipose tissue in both obese adults and the paediatric population.Reference Iacobellis, Corradi and Sharma19 Therefore, the relationship between epicardial adipose tissue and insulin resistance and cardiovascular diseases in adult and paediatric obese patients has been investigated in many studies, and an association between epicardial adipose tissue and these diseases has been demonstrated.Reference Iacobellis, Ribaudo and Assael22,Reference Gastaldelli, Morales, Marraccini and Sicari23 In a study, it was shown that epicardial adipose tissue predicts insulin resistance.Reference Güneş, Güneş and Temiz24 The first-line treatment of obese children with insulin resistance includes diet plan, lifestyle change and increased physical activity.Reference Tagi, Giannini and Chiarelli5 Pharmacological treatment is used in cases when primary prevention methods fail. Metformin is the first-choice drug for reducing insulin resistance. Metformin inhibits liver gluconeogenesis, increases peripheral glucose intake and decreases insulin demand, thereby decreases insulin resistance.Reference Wróbel, Marek, Kajdaniuk, Rokicka, Szymborska-Kajanek and Strojek25 The effect of metformin on body weight and visceral adipose tissue has also been investigated in some studies and demonstrated metformin significantly decreases body weight in children with insulin resistance.Reference Yanovski, Krakoff and Salaita26 Both reduced insulin resistance and reduced visceral adipose tissue may cause epicardial adipose tissue. The effect of metformin use on epicardial adipose tissue was investigated, and it decreases the epicardial adipose tissue.Reference Ziyrek, Kahraman, Ozdemir and Dogan13 Similarly, metformin use in obese children with insulin resistance decreased epicardial adipose tissues in our study.

It has been demonstrated that atrial electromechanical delay predicts arrhythmias in studies conducted with adults and children.Reference Temiz, Güneş and Güneş12Reference Yagmur, Cansel and Acikgoz28 Although its mechanism has not been completely understood in obesity, pro-inflammatory cytokines like interleukin-1, interleukin-6 and tumour necrosis factor-α which are secreted from visceral and epicardial adipose tissue may cause atrial electromechanical delay by causing inflammation in atrial tissue.Reference Nerlekar, Brown and Muthalaly29 A decrease in visceral and epicardial adipose tissue may also cause a decrease in electromechanical delay by further reducing existing inflammation. In our study, a decrease in electromechanical delay after metformin may be explained by the decreasing effect of metformin use on epicardial adipose tissue and body mass index. Besides, metformin may demonstrate its anti-inflammatory effects by activating protein kinase activated by adenylate monophosphate, antioxidant activity and insulin sensitivity and then this anti-inflammatory effect may cause improvement in electromechanical delay by suppressing inflammation in atrial tissue.Reference Saisho30,Reference Zheng, Chen and Li31

Metformin inhibits hepatic glucose production by inhibiting direct and indirect gluconeogenesis in the liver, improves insulin-sensitive glucose utilisation in muscle tissue, increases levels of the kinase activity of insulin receptors and glucose transporter type 4, reduces insulin resistance in post-receptor level and causes a reduction in visceral adipose tissue with these effects.Reference Rena, Hardie and Pearson32 In our study, it was also demonstrated that serum insulin values, body mass index, Homeostatic Model Assessment for Insulin Resistance and the body weight of the patients decreased after metformin treatment.

Conclusion

To the best of our knowledge, our study is the first study demonstrating the decreasing effect of metformin use on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance. Metformin use in obese children with insulin resistance may provide a reduction in cardiovascular complications in their future life by providing a significant decrease in epicardial adipose tissue and atrial electromechanical delay values. Metformin could become the aspirin of the 21st century for obesity.

There are some limitations to our study. The main limitation is small sample size. Lack of inflammatory marker measurement is another limitation. Echocardiographic epicardial adipose tissue measurement is a linear measurement and it may not be able to evaluate total epicardial adipose volume in various myocardial localisations. MRI may be more sensitive in the evaluation of total epicardial adipose tissue. Also, not being able to demonstrate an association between waist circumference and epicardial adipose tissue due to a lack of measurement of waist circumference is another limitation. Additionally, intra-observer electromechanical delay was not evaluated. Inter-atrial and intra-atrial electromechanical delay obtained by tissue doppler investigation was not correlated with invasive inter-atrial and intra-atrial electromechanical delay. In conclusion, further detailed studies with larger samples are needed for clarifying the positive effects of metformin on epicardial adipose tissue and electromechanical delay values of obese children and its underlying mechanisms.

Acknowledgements

None.

Financial Support

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflict of Interest

None.

Ethical Standards

This study was approved by the Ethical Committee of Kahramanmaraş Sütçü İmam University School of Medicine. Parental consent was obtained using an opt-out approach.

References

World Health Organization. Global and regional trends by UN Regions, 1990–2025; Overweight: 1990–2015 June 2016. Retrieved April 14, 2020 from http://apps.who.int/gho/data/node.main.NUTUNREGIONS? Google Scholar
Lobstein, T, Jackson-Leach, R, Moodie, ML, et al. Child and adolescent obesity: part of a bigger picture. Lancet 2015; 385: 25102520.CrossRefGoogle ScholarPubMed
de Onis, M, Blössner, M, Borghi, E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010; 92: 12571264.CrossRefGoogle ScholarPubMed
Iacobellis, G, Leonetti, F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab 2005; 90: 63006302.CrossRefGoogle ScholarPubMed
Tagi, VM, Giannini, C, Chiarelli, F. Insulin resistance in children. Front Endocrinol (Lausanne) 2019; 4: 342.CrossRefGoogle Scholar
Akhlaghi, F, Matson, KL, Mohammadpour, AH, Kelly, M, Karimani, A. Clinical pharmacokinetics and pharmacodynamics of antihyperglycemic medications in children and adolescents with type 2 diabetes mellitus. Clin Pharmacokinet 2017; 56: 561571.CrossRefGoogle ScholarPubMed
Chao, AM, Wadden, TA, Berkowitz, RI., Chao, AM, Wadden, TA. The safety of pharmacologic treatment for pediatric obesity. Expert Opin Drug Safety 2018; 17: 379385.CrossRefGoogle ScholarPubMed
Khokhar, A, Umpaichitra, V, Chin, VL, Perez-Colon, S. Metformin use in children and adolescents with prediabetes. Pediatr Clin N Am 2017; 64: 13411353.CrossRefGoogle ScholarPubMed
Schmidt, M, Bøtker, HE, Pedersen, L, Sørensen, HT. Young adulthood obesity and risk of acute coronary syndromes, stable angina pectoris, and congestive heart failure: a 36-year cohort study. Ann Epidemiol 2014; 24: 356361.e1.CrossRefGoogle ScholarPubMed
Sommer, A, Twig, G. The impact of childhood and adolescent obesity on cardiovascular risk in adulthood: a systematic review. Curr Diab Rep 2018; 18: 91.CrossRefGoogle ScholarPubMed
El-Assaad, I, Al-Kindi, SG, Saarel, EV, Aziz, PF. Lone pediatric atrial fibrillation in the United States: analysis of over 1500 cases. Pediatr Cardiol 2017; 38: 10041009.CrossRefGoogle ScholarPubMed
Temiz, F, Güneş, H, Güneş, H. Evaluation of atrial electromechanical delay in children with obesity. Medicina (Kaunas) 2019; 55: E228.CrossRefGoogle ScholarPubMed
Ziyrek, M, Kahraman, S, Ozdemir, E, Dogan, A. Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients. Rev Port Cardiol 2019; 38: 419423.CrossRefGoogle ScholarPubMed
van der Aa, MP, Fazeli Farsani, S, Kromwijk, LA, de Boer, A, Knibbe, CA, van der Vorst, MM. How to screen obese children at risk for type 2 diabetes mellitus? Clin Pediatr (Phila) 2014; 53: 337342.CrossRefGoogle ScholarPubMed
Shashaj, B, Luciano, R, Contoli, B, et al. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta Diabetol 2016; 53: 251260.CrossRefGoogle ScholarPubMed
Iacobellis, G., Lonn, E., Lamy, A. Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol 2011; 146: 452454.CrossRefGoogle ScholarPubMed
Gunes, H, Sokmen, A, Kaya, H, et al. Evaluation of atrial electromechanical delay to predict atrial fibrillation in hemodialysis patients. Medicina (Kaunas) 2018; 54: E58.CrossRefGoogle ScholarPubMed
Gastaldelli, A, Basta, G. Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis 2010; 20: 481490.CrossRefGoogle ScholarPubMed
Iacobellis, G, Corradi, D, Sharma, AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005; 2: 536543.CrossRefGoogle ScholarPubMed
Schejbal, V. Epicardial fatty tissue of the right ventricle morphology, morphometry and functional significance. Pneumologie 1989; 43: 490499.Google ScholarPubMed
Marchington, JM, Mattacks, CA, Pond, CM. Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comp Biochem Physiol B 1989; 94: 225232.CrossRefGoogle ScholarPubMed
Iacobellis, G, Ribaudo, MC, Assael, F, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003; 88: 51635168.CrossRefGoogle ScholarPubMed
Gastaldelli, A, Morales, MA, Marraccini, P, Sicari, R. The role of cardiac fat in insulin resistance. Curr Opin Clin Nutr Metab Care 2012; 15: 523528.CrossRefGoogle ScholarPubMed
Güneş, H, Güneş, H, Temiz, F. The relationship between epicardial adipose tissue and insulin resistance in obese children. Arq Bras Cardiol 2020; 114: 675682.Google ScholarPubMed
Wróbel, MP, Marek, B, Kajdaniuk, D, Rokicka, D, Szymborska-Kajanek, A, Strojek, K. Metformin - a new old drug. Endokrynol Pol 2017; 68: 482496.CrossRefGoogle ScholarPubMed
Yanovski, JA, Krakoff, J, Salaita, CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011; 60: 477485.CrossRefGoogle ScholarPubMed
Erdem, FH, Ozturk, S, Baltaci, D,et al. Detection of atrial electromechanical dysfunction in obesity. Acta Cardiol 2015; 70: 678684.CrossRefGoogle ScholarPubMed
Yagmur, J, Cansel, M, Acikgoz, N, et al. Assessment of atrial electromechanical delay by tissue Doppler echocardiography in obese subjects. Obesity (Silver Spring). 2011; 19: 779783.CrossRefGoogle ScholarPubMed
Nerlekar, N, Brown, AJ, Muthalaly, RG, et al. Association of epicardial adipose tissue and high-risk plaque characteristics: a systematic review and meta-analysis. J Am Heart Assoc 2017; 6: e006379.CrossRefGoogle ScholarPubMed
Saisho, Y. Metformin and inflammation: its potential beyond glucose lowering effect. Endocr Metab Immune Disord Drug Targets 2015; 15: 196205.CrossRefGoogle ScholarPubMed
Zheng, Z, Chen, H, Li, J, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012; 61: 217228.CrossRefGoogle ScholarPubMed
Rena, G, Hardie, DG, Pearson, ER. The mechanisms of action of metformin. Diabetologia 2017; 60: 15771585.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Baseline characteristics of study patients

Figure 1

Figure 1. The comparison of epicardial adipose tissue thickness (EAT) values before and after metformin therapy

Figure 2

Table 2. Comparison of the atrial electromechanical coupling parameters measured by tissue Doppler imaging